Glenmark’s US Growth Continues with Acetylcysteine Injection Launch

Glenmark Pharmaceuticals Ltd has also established itself in the US market by acquiring Aspen Pharma USA Inc's generic injectable Acetylcysteine. The acquisition, whose value remains confidential, aligns with Glenmark's strategy to enhance its hospital segment functions.

The resultant drug—Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) in single-use vials—is employed for the treatment of acetaminophen overdose. The company's introduction assures that its medication is anticipated to demonstrate the same therapeutic benefits as Acetadote Injection from Cumberland Pharmaceuticals Inc.

Commenting on the development, Marc Kikuchi, Glenmark President & Business Head in North America, said, "This is a great addition to our injectable portfolio in the US market as we continue to drive growth for the hospital segment."

Glenmark Pharmaceuticals has been advancing in the international generic market, concentrating on complex generics and injectables. Leveraging its robust research-led model, the company has brought to market a chain of products that are specially positioned to cater to the needs of critical care. This buy is in line with Glenmark's strategy of building its injectable portfolio and further making its mark in the competitive US pharma market.